THB001
Chronic Spontaneous Urticaria (CSU)
Key Facts
About Third Harmonic Bio
Third Harmonic Bio is pioneering a new approach to treating mast cell-driven diseases by developing highly selective, oral KIT inhibitors. The company's lead program, THB001, is in Phase 1b clinical trials for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), with a pipeline targeting other mast cell-mediated conditions. Founded by experienced biotech leaders and backed by top-tier investors, the company aims to address significant unmet needs in allergy and inflammation with a precision medicine strategy.
View full company profileAbout Third Harmonic Bio
Third Harmonic Bio is pioneering a new approach to treating mast cell-driven diseases by developing highly selective, oral KIT inhibitors. The company's lead program, THB001, is in Phase 1b clinical trials for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), with a pipeline targeting other mast cell-mediated conditions. Founded by experienced biotech leaders and backed by top-tier investors, the company aims to address significant unmet needs in allergy and inflammation with a precision medicine strategy.
View full company profileTherapeutic Areas
Other Chronic Spontaneous Urticaria (CSU) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barzolvolimab (CDX-0159) | Celldex Therapeutics | Phase 2b |